Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity

8 Aug 2017

Abstract excerpt

// Gloria Mittica 1, 2, * , Eleonora Ghisoni 1, 2, * , Gaia Giannone 1, 2 , Massimo Aglietta 1, 2 , Sofia Genta 1, 2 and Giorgio Valabrega 1, 2 1 Department of Oncology, University of Turin, Turin, Italy 2 Division of Medical Oncology-1, Candiolo Cancer Institute-FPO- IRCCS, Candiolo, Italy * These authors contributed equally to this work Correspondence to: Giorgio Valabrega, email: giorgio.valabrega@ircc.it...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Endometrial and Cervical Cancer Treatments
Share to Ferroptosis and cancer prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29163851
DOI: 10.18632/oncotarget.20042

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activityPMID 29163851Read ↗

Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?Semantic proximity Read ↗

New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere.Semantic proximity Read ↗

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibitionSemantic proximity Read ↗

The Clinical and Pathological Characteristics of POLE-Mutated Endometrial Cancer: A Comprehensive ReviewSemantic proximity Read ↗

Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.Semantic proximity Read ↗

Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection.Semantic proximity Read ↗

Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies.Semantic proximity Read ↗

Tailoring Endometrial Cancer Treatment Based on Molecular Pathology: Current Status and Possible Impacts on Systemic and Local Treatment.Semantic proximity Read ↗

Molecular Characterization and Clinical Implications of Endometrial Cancer.Semantic proximity Read ↗

Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.Semantic proximity Read ↗

Endometrial Cancer: Transitioning from Histology to Genomics.Semantic proximity Read ↗

The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment DecisionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.